Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study - Concepedia

Concepedia

Publication | Open Access

Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study

DOI Full Paper Access

88

Citations

28

References

2022

Year

Carrie L. Kitko, Mukta Arora, Zachariah DeFilipp, Mohammad Abu Zaid, Antonio Di Stasi, Vedran Radojčić, Courtney B. Betts, Lisa M. Coussens, Michael L. Meyers, Hope Qamoos,

Journal of Clinical Oncology

Abstract

Targeting profibrotic macrophages with axatilimab is a therapeutically promising novel strategy with a favorable safety profile for refractory cGVHD.

References

	Year	Citations

Page 1